×
About 54,025 results

ALLMedicine™ Small Cell Lung Cancer Center

Research & Reviews  16,863 results

Altered splicing of ATG16-L1 mediates acquired resistance to tyrosine kinase inhibitors...
https://doi.org/10.1002/1878-0261.13229
Molecular Oncology; Hatat AS, Benoit-Pilven C et. al.

May 21st, 2022 - Despite the initial efficacy of using tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR-TKIs) for treating patients with non-small cell lung cancer (NSCLC), resistance inevitably develops. Recent studies highlight a link between...

Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus...
https://doi.org/10.1080/14737167.2022.2078310
Expert Review of Pharmacoeconomics & Outcomes Research; de Alava E, Pareja MJ et. al.

May 21st, 2022 - To assess the cost-effectiveness of using next-generation sequencing (NGS) compared to sequential single-testing (SST) for molecular diagnostic and treatment of patients with advanced non-small cell lung cancer (NSCLC) from a Spanish single-center...

Persistent dry cough
https://www.mdedge.com/lung-cancer-challenge-center/article/254800/lung-cancer/persistent-dry-cough

May 20th, 2022 - On the basis of the patient's presentation, history, and imaging results, the likely diagnosis is metastatic small cell lung cancer (SCLC). Most patients with SCLC present with hematogenous metastases; only about one third present with limited dis.

Non-Small Cell Lung Cancer (NSCLC)
https://emedicine.medscape.com/article/279960-overview

May 20th, 2022 - Practice Essentials Non–small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Histologically, NSCLC is divided into adenocarcinoma, squamous cell carcinoma (SCC) (see the image below), and large cell carcinoma. Patient...

Non-Small Cell Lung Cancer (NSCLC)
http://emedicine.medscape.com/article/279960-overview

May 20th, 2022 - Practice Essentials Non–small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Histologically, NSCLC is divided into adenocarcinoma, squamous cell carcinoma (SCC) (see the image below), and large cell carcinoma. Patient...

see more →

Guidelines  27 results

Canadian Consensus Recommendations on the Management of MET-Altered NSCLC.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628757
Current Oncology (Toronto, Ont.); Cheema PK, Banerji SO et. al.

Dec 14th, 2021 - In Canada, the therapeutic management of patients with advanced non-small cell lung cancer (NSCLC) with rare actionable mutations differs between provinces, territories, and individual centres based on access to molecular testing and funded treatm...

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2021.0058
Journal of the National Comprehensive Cancer Network : JN... Ganti AKP, Loo BW et. al.

Dec 14th, 2021 - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment...

Definition and assessment of high risk in patients considered for lobectomy for stage I...
https://doi.org/10.1016/j.jtcvs.2021.07.030
The Journal of Thoracic and Cardiovascular Surgery; Pennathur A, Brunelli A et. al.

Oct 31st, 2021 - Lobectomy is a standard treatment for stage I non-small cell lung cancer, but a significant proportion of patients are considered at high risk for complications, including mortality, after lobectomy and might not be candidates. Identifying who is ...

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.
https://doi.org/10.6004/jnccn.2021.0013
Journal of the National Comprehensive Cancer Network : JN... Ettinger DS, Wood DE et. al.

Mar 6th, 2021 - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines regarding targete...

Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHES...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177089
Chest Mazzone PJ, Gould MK et. al.

Apr 27th, 2020 - The risks from potential exposure to coronavirus disease 2019 (COVID-19), and resource reallocation that has occurred to combat the pandemic, have altered the balance of benefits and harms that informed current (pre-COVID-19) guideline recommendat...

see more →

Drugs  172 results see all →

Clinicaltrials.gov  1,544 results

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
https://clinicaltrials.gov/ct2/show/NCT02194738

May 20th, 2022 - PRIMARY OBJECTIVES: I. To centrally test resected non-small cell lung cancer (NSCLC) for genetic mutations to facilitate accrual to randomized adjuvant studies. II. To obtain clinically annotated tumor tissue and patient-matched non-malignant deox...

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Trip...
https://clinicaltrials.gov/ct2/show/NCT02484404

May 20th, 2022 - Background: Disruption of the immune checkpoint PD-1/PD-L1 pathway yielded clinical activity in subsets of advanced solid tumors, such as melanoma and lung cancer. Olaparib (O), a PARP inhibitor (PARPi), has demonstrated single agent activity in r...

PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
https://clinicaltrials.gov/ct2/show/NCT04209595

May 20th, 2022 - Background: We hypothesize that a dose-escalation strategy that incorporates tumor targeted DNA-damaging chemotherapy and DNA-damage response (DDR) inhibitors could allow safe and effective administration of DDR inhibitor-chemotherapy combination....

Tumor-specific T Cells in Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT02515760

May 20th, 2022 - Non-small cell lung cancer is characterized by aggressive growth and treatment resistance. New approaches include immunotherapeutic strategies but spontaneous immune responses against tumor antigens remain unclear. The aim of this study is to char...

New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy
https://clinicaltrials.gov/ct2/show/NCT04564157

May 20th, 2022 - This is an open-label, randomised, two-arm, phase III, multicentre clinical trial.The total sample size is 210 and 105 per arm. The population to be included are stage IB-IIIA, completely resected, non-small cell lung cancer patients. Patients ran...

see more →

News  3,003 results

Persistent dry cough
https://www.mdedge.com/lung-cancer-challenge-center/article/254800/lung-cancer/persistent-dry-cough

May 20th, 2022 - On the basis of the patient's presentation, history, and imaging results, the likely diagnosis is metastatic small cell lung cancer (SCLC). Most patients with SCLC present with hematogenous metastases; only about one third present with limited dis.

Genomic Testing Challenges Persist
https://www.onclive.com/view/genomic-testing-challenges-persist

May 5th, 2022 - Although molecular biomarkers are becoming increasingly relevant in cancer care, community oncologists confront a plethora of challenges in translating research findings into practice. Structural changes in payment systems and decision-support too...

Updates in Treatment of HER2 Mutant NSCLC
https://www.onclive.com/view/updates-in-treatment-of-her2-mutant-nsclc

May 5th, 2022 - Ben Levy, MD: Let’s shift gears to HER2 exon 20, which isn’t to be confused with EGFR exon 20. Not all HER2 is exon 20, but most are. Misako, do you want to walk us through this? We’ve got some very exciting data coming down the pike for these mut...

JDQ443 Demonstrates Early Efficacy Signals in KRAS G12C-Mutant Solid Tumors
https://www.onclive.com/view/jdq443-demonstrates-early-efficacy-signals-in-kras-g12c-mutant-solid-tumors

May 2nd, 2022 - The novel KRAS G12C inhibitor, JDQ443, demonstrated early efficacy signals and a tolerable safety profile in initial data from the dose-escalation portion of the phase 1b/2 KontRASt-01 (NCT04699188) trial presented at the 2022 AACR Annual Meeting....

Sotorasib Shows Impressive 2-Year OS Rate in KRAS G12C+ NSCLC
https://www.onclive.com/view/sotorasib-shows-impressive-2-year-os-rate-in-kras-g12c-nsclc

May 2nd, 2022 - Sotorasib (Lumakras) demonstrated an overall survival (OS) rate of 32.5% (95% CI, 25.0%-40.2%) at 2 years in patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC), according to longer follow-up data from the phase 1/2 CodeBreaK 100 tri...

see more →

Patient Education  1 results see all →